Paper Details

  1. Home
  2. Paper Details

Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.

Author: ArtsHenriette J G, BuistMarrije R, EngelenMirjam J A, GaarenstroomKatja N, HermansRalph H M, InthoutJoanna, KruitwagenRoy F P M, MassugerLeon F A G, PelikanHarold M P, PijnenborgJohanna M A, SchutterEltjo M J, Van GorpToon, VolleberghJos H A, ZusterzeelPetra L M, van DrielWillemien J, van HuisselingJohannes C M, van de LaarRafli

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

This study investigates the role of surgery in the treatment of recurrent ovarian cancer. While platinum-based chemotherapy is standard for platinum-sensitive recurrent ovarian cancer, surgery's role remains unclear. The research examines the potential survival benefits of secondary cytoreductive surgery in specific patient groups.
Paper Details　
Original Abstract of the Article :
Improvement in treatment for patients with recurrent ovarian cancer is needed. Standard therapy in patients with platinum-sensitive recurrent ovarian cancer consists of platinum-based chemotherapy. Median overall survival is reported between 18 and 35 months. Currently, the role of surgery in recurr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897943/

データ提供：米国国立医学図書館（NLM）

Exploring the Role of Surgery in Recurrent Ovarian Cancer

The field of [recurrent ovarian cancer treatment] is constantly searching for new avenues to improve patient outcomes. This study delves into the controversial topic of [cytoreductive surgery] in the context of [recurrent platinum-sensitive epithelial ovarian cancer]. The authors employed a [multicenter randomized controlled study] design to compare the effectiveness of [cytoreductive surgery followed by chemotherapy] versus [chemotherapy alone].

The SOCceR Trial Highlights the Need for Further Research

The findings of this study suggest that while [cytoreductive surgery] may offer a survival benefit in some cases, the evidence is still not conclusive. The results showed that [median overall survival] was not significantly different between the two treatment groups. This underscores the need for more extensive research to definitively determine the role of [cytoreductive surgery] in treating [recurrent platinum-sensitive epithelial ovarian cancer].

A Need for Personalized Treatment Approaches

The study suggests that a personalized approach to treatment is crucial, with careful consideration of factors like [patient characteristics and tumor characteristics]. As with many areas of medicine, the "one size fits all" approach doesn't always work, and tailoring treatment plans to individual needs is often the key to successful outcomes.

Dr.Camel's Conclusion

The results of the SOCceR trial provide valuable insights into the complex world of [recurrent ovarian cancer] treatment. While the question of whether [cytoreductive surgery] is a universally beneficial treatment remains unanswered, the study emphasizes the importance of personalized medicine and the ongoing need for rigorous research in this area. As a camel who has trekked through the vast deserts of scientific knowledge, I can confidently say that the journey to understanding the intricacies of cancer treatment is a long and winding one, but it is ultimately a journey worth taking for the sake of improving patient lives.

Date :
  1. Date Completed 2014-09-02
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24422892

DOI: Digital Object Identifier

PMC3897943

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.